BreezeBio banks $60M to make more precise genetic medicines [Yahoo! Finance]
ROCHE HOLDING LTD S/ADR (RHHBY)
NASDAQ:AMEX Investor Relations:
roche.com/investors.htm
Company Research
Source: Yahoo! Finance
Dive Brief: Genetic medicines maker BreezeBio said Wednesday it raised $60 million in a Series B round, backed by more than a dozen investors across Asia and the U.S. Formerly known as GenEdit, the South San Francisco, California-based startup was built around an alternative method of delivering gene-based medicines that involves specialized nanoparticles. The company has changed its name to reflect a newfound push to develop its own treatments, with a focus on autoimmune diseases and oncology. BreezeBio's lead program, codenamed BRZ-101, is designed to coerce the body into stifling the damaging autoimmune response in Type 1 diabetes. The company is advancing that therapy this year into the final preclinical studies that come before human testing. Dive Insight: BreezeBio has spent a decade sharpening a delivery technology it refers to as “NanoGalaxy.” Founded by CEO Kunwoo “Ryan” Lee and other researchers at the University of California, Berkeley, the startup was one of m
Show less
Read more
Impact Snapshot
Event Time:
RHHBY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RHHBY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RHHBY alerts
High impacting ROCHE HOLDING LTD S/ADR news events
Weekly update
A roundup of the hottest topics
RHHBY
News
- Parker Institute for Cancer Immunotherapy Announces Appointment of Bob Purcell as Chief Communications Officer [Yahoo! Finance]Yahoo! Finance
- Flatiron Health Attends the 2026 American Society of Genitourinary Cancers Symposium to Answer Oncology's Most Critical QuestionsBusiness Wire
- FDA Approves Genentech’s Venclexta® Plus Acalabrutinib Combination Regimen for Previously Untreated Chronic Lymphocytic LeukemiaBusiness Wire
- FDA Accepts New Drug Application for Genentech's Giredestrant in ESR1-Mutated, ER-Positive Advanced Breast Cancer [Yahoo! Finance]Yahoo! Finance
- FDA accepts New Drug Application for Roche's giredestrant in ESR1-mutated, ER-positive advanced breast cancer [Yahoo! Finance]Yahoo! Finance